Please try another search
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.
Name | Age | Since | Title |
---|---|---|---|
Michael Stephen Wyzga | 68 | 2020 | Independent Non-Executive Chairman of The Board |
Marc J. Yoskowitz | 48 | 2022 | Independent Director |
Denise Scots-Knight | 64 | 2015 | Co-Founder, CEO & Executive Director |
Pierre Jacquet | 55 | 2021 | Independent Director |
Jeremy Bender | 51 | 2020 | Independent Non Executive Director |
Daniel A. Shames | 77 | 2022 | Independent Director |
Annalisa Mary Jenkins | 58 | 2022 | Independent Director |
Justin Roberts | 40 | 2022 | Independent Director |
Deepika Rachel Pakianathan | 59 | 2019 | Independent Non-Executive Director |
Anders Ekblom | 70 | 2015 | Independent Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review